Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

BACKGROUND: Immune-mediated diarrhea and colitis (IMDC) can limit immune checkpoint inhibitors (ICIs) treatment, which is efficacious for advanced malignancies. Steroids and infliximab are commonly used to treat it. These agents induce systemic immunosuppression, with its associated morbidity. We as...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Abu-Sbeih, Hamzah, Ali, Faisal S., Alsaadi, Dana, Jennings, Joseph, Luo, Wenyi, Gong, Zimu, Richards, David M., Charabaty, Aline, Wang, Yinghong
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6280383/
https://ncbi.nlm.nih.gov/pubmed/30518410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0461-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars